हिंदी में पढ़ें

Aurobindo Pharma

Aurobindo Pharma unit gets first product approval from USFDA

Aurobindo Pharma unit gets first product approval from USFDA

Wed, Sep 11, 2024

The new injectable facility of Eugia Steriles, a subsidiary of Eugia Pharma Specialities and a stepdown unit of the company, situated at Anakapalli District of Andhra Pradesh was inspected by the US FDA from March 28 to April 5 this year.

Aurobindo Pharma arm gets warning letter from USFDA for formulations unit in Telangana

Aurobindo Pharma arm gets warning letter from USFDA for formulations unit in Telangana

Fri, Aug 16, 2024

Aurobindo Pharma Ltd's subsidiary Eugia Pharma Specialities Ltd has received a warning letter from the USFDA for its Telangana-based formulation manufacturing unit. This follows the unit's earlier classification as 'Official Action Indicated' (OAI). Despite this, the company assures there is no impact on current US market supplies and remains committed to improving compliance with FDA regulations.

Analyzing Aurobindo Pharma's Recent Action

Analyzing Aurobindo Pharma's Recent Action

Mon, Jul 15, 2024

Why is Aurobindo Pharma in action? Board meeting on July 18, big decision possible. Know complete details from Nupur.

TRENDING NOW

Aurobindo Pharma shares jump after its subsidiary inks deal with Singapore firm

Aurobindo Pharma shares jump after its subsidiary inks deal with Singapore firm

Thu, Oct 12, 2023

Aurobindo Pharma said on Wednesday that its subsidiary, CuraTeQ, has signed a letter of intent with a Singapore-based company, Merck Sharp & Dohme Singapore Trading Pte. Ltd. and its affiliates, for CMO operations.

Aurobindo Pharma shares scale 52-week high; here is what is driving the stock

Aurobindo Pharma shares scale 52-week high; here is what is driving the stock

Fri, Sep 29, 2023

Aurobindo Pharma surged on Friday, trading in huge volumes, after sources told Zee Business that the company received approval to launch its Revlimid drug.

Aurobindo Pharma shares slip 3% as company's US arm recalls different drugs due to manufacturing lapses

Aurobindo Pharma shares slip 3% as company's US arm recalls different drugs due to manufacturing lapses

Tue, Aug 22, 2023

The stock came under pressure after reports said that Aurobindo Pharma, along with Alembic Pharmaceuticals, is recalling different products in the US market due to manufacturing lapses.

Alembic, Aurobindo recall drugs in US market

Alembic, Aurobindo recall drugs in US market

Tue, Aug 22, 2023

As per the US health regulator's latest Enforcement Report, the US-based subsidiary of Alembic Pharmaceuticals is recalling 82,400 bottles of Tobramycin Ophthalmic Solution in the American market.

Aurobindo Pharma launches HIV triple combination product for children

Aurobindo Pharma launches HIV triple combination product for children

Thu, Aug 17, 2023

The generic drug has received tentative approval from the USFDA under the US President's Emergency Plan for AIDS Relief (PEPFAR) Programme. The drug will be used in the treatment of children aged three months or older between 6-25 kg in weight in the low and middle income countries, including India.

Aurobindo Pharma's subsidiary Eugia Pharma Specialities gets USFDA nod for Icatibant injection

Aurobindo Pharma's subsidiary Eugia Pharma Specialities gets USFDA nod for Icatibant injection

Wed, Aug 16, 2023

"The Company in connection with USFDA approval received by Eugia Pharma Specialities Limited, a wholly owned subsidiary of the company, for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe," the filing read.

Aurobindo Pharma shares hit a 52-week high after US FDA's approval

Aurobindo Pharma shares hit a 52-week high after US FDA's approval

Mon, Aug 07, 2023

The shares, at 10:36 am, are trading up 1.81 per cent at Rs 857.00 to hit a 52-week high. The day's high so far has been Rs 864.45.

Why Aurobindo Pharma Shares Jump 7% Despite Drop In Q4 Profits?

Why Aurobindo Pharma Shares Jump 7% Despite Drop In Q4 Profits?

Tue, May 30, 2023

Pharma sector giant Aurobindo Pharma has announced the results for the fourth quarter. Pharma giant Aurobindo Pharma's profit declined by more than 12 percent to Rs 506 crore. Why did Aurobindo Pharma shares surge after the results? Know the complete details in this video.

Aurobindo Pharma Q4 Result Preview: PAT Likely To Decline 11% Yoy; US Sales May Grow Up To 18%

Aurobindo Pharma Q4 Result Preview: PAT Likely To Decline 11% Yoy; US Sales May Grow Up To 18%

Fri, May 26, 2023

Aurobindo Pharma Q4 result preview: Revenue may see a growth of 9 per cent to Rs 6,316 crore against Rs 5,809 crore logged in the year-ago period.

Aurobindo Pharma Q4 result preview: PAT likely to decline 11% YoY; US sales may grow up to 18%

Aurobindo Pharma Q4 result preview: PAT likely to decline 11% YoY; US sales may grow up to 18%

Thu, May 25, 2023

Aurobindo Pharma Q4 result preview: Revenue may see a growth of 9 per cent to Rs 6,316 crore against Rs 5,809 crore logged in the year-ago period.

Aurobindo Pharma: Investors Should Love Or Hate, How is Company's Fundamental & Growth Outlook?

Aurobindo Pharma: Investors Should Love Or Hate, How is Company's Fundamental & Growth Outlook?

Tue, Feb 14, 2023

This Valentine's Day know why to love and why to hate Aurobindo Pharma shares from Nupur and Arman. Watch this video for more details.

Valentine’s Day 2023 special stocks: RBL Bank, Aurobindo, Vodafone Idea, Paytm, IRCTC and more

Valentine’s Day 2023 special stocks: RBL Bank, Aurobindo, Vodafone Idea, Paytm, IRCTC and more

Tue, Feb 14, 2023

On Valentine’s Day 2023, Zee Business brings you a special edition of ‘Love Me or Hate Me’ – wherein analysts recommend shares to buy or avoid.

Aurobindo Pharma Shares Gain Even As Q3 Profit Sinks; Board Declares 300% Dividend

Aurobindo Pharma Shares Gain Even As Q3 Profit Sinks; Board Declares 300% Dividend

Fri, Feb 10, 2023

Pharma giant Aurobindo Pharma has announced an interim dividend of 300 per cent along with the December quarter results. The share of US business in the total business of the company has reached about 46.8%. Know the big things of Aurobindo Pharma's concall from Nupur.

Aurobindo Pharma Q3 Results Preview: How Will Be The Profit & Margin Of Aurobindo Pharma In Q3?

Aurobindo Pharma Q3 Results Preview: How Will Be The Profit & Margin Of Aurobindo Pharma In Q3?

Thu, Feb 09, 2023

Today the results of Aurobindo Pharma will come. How will be the results of Aurobindo Pharma in Q3? How will be the profits and margins in Q3? Know from Nupur.

Aurobindo Pharma gains day after ED action in Delhi excise policy case

Aurobindo Pharma gains day after ED action in Delhi excise policy case

Fri, Nov 11, 2022

Recovering the lost ground, the company's shares were trading in the green on the BSE as well as NSE on Friday morning.

Global brokerage bullish on these super 5 stocks in this week kno full list

Global brokerage bullish on these super 5 stocks in this week kno full list

Sun, Aug 21, 2022

global brokerage buy call on these top 5 stocks to investors for this week. Here you know full list and can add these stocks in your portfolio.

SEBI issues warning letter to Aurobindo Pharma over US FDA audit

SEBI issues warning letter to Aurobindo Pharma over US FDA audit

Mon, Jun 27, 2022

The Securities and Exchange Board of India (SEBI) on Monday issued a warning letter to pharmaceutical manufacturing company Aurobindo Pharma. The warning letter has been issued for not sharing complete information related to the United States Food and Drug Administration (US FDA). Zee Business report.

Global View: Infosys, Aurobindo Pharma, United Spirits, Astral and Dixon Tech can give 6-49% return

Global View: Infosys, Aurobindo Pharma, United Spirits, Astral and Dixon Tech can give 6-49% return

Wed, Jun 01, 2022

Indian markets on Tuesday made a flat opening as Nifty opened near 16600 levels and Sensex 55,600. Nifty Metal and FMCG were top sectoral gainers in early morning trade.

Aurobindo Pharma, JSPL, Medplus Health, Delhivery, and Campus shares surge after Q4 results – know what brokerages/analyst say

Aurobindo Pharma, JSPL, Medplus Health, Delhivery, and Campus shares surge after Q4 results – know what brokerages/analyst say

Tue, May 31, 2022

Shares of Aurobindo Pharma, Jindal Power Steel, Medplus Health, Delhivery and Campus Activewear surged up to 4 per cent on the BSE intraday during Tuesday’s trading session.

First on Zee Business: Negative News For Aurobindo Pharma

First on Zee Business: Negative News For Aurobindo Pharma

Thu, May 12, 2022

A setback for Aurobindo Pharma. Government withdraws anti-dumping duty from Amoxicillin TriHydrate. Finance Ministry issued notification. Duty was imposed on 16 May 2017. Watch this video to know full news from Ambarish Pandey.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x